Literature DB >> 24172539

Modeling the Adenoma and Serrated pathway to Colorectal CAncer (ASCCA).

Marjolein J E Greuter1, Xiang-Ming Xu, Jie-Bin Lew, Evelien Dekker, Ernst J Kuipers, Karen Canfell, Gerrit A Meijer, Veerle M H Coupé.   

Abstract

Several colorectal cancer (CRC) screening models have been developed describing the progression of adenomas to CRC. Currently, there is increasing evidence that serrated lesions can also develop into CRC. It is not clear whether screening tests have the same test characteristics for serrated lesions as for adenomas, but lower sensitivities have been suggested. Models that ignore this type of colorectal lesions may provide overly optimistic predictions of the screen-induced reduction in CRC incidence. To address this issue, we have developed the Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) model that includes the adenoma-carcinoma pathway and the serrated pathway to CRC as well as characteristics of colorectal lesions. The model structure and the calibration procedure are described in detail. Calibration resulted in 19 parameter sets for the adenoma-carcinoma pathway and 13 for the serrated pathway that match the age- and sex-specific adenoma and serrated lesion prevalence in the COlonoscopy versus COlonography Screening (COCOS) trial, Dutch CRC incidence and mortality rates, and a number of other intermediate outcomes concerning characteristics of colorectal lesions. As an example, we simulated outcomes for a biennial fecal immunochemical test screening program and a hypothetical one-time colonoscopy screening program. Inclusion of the serrated pathway influenced the predicted effectiveness of screening when serrated lesions are associated with lower screening test sensitivity or when they are not removed. To our knowledge, this is the first model that explicitly includes the serrated pathway and characteristics of colorectal lesions. It is suitable for the evaluation of the (cost)effectiveness of potential screening strategies for CRC.
© 2013 Society for Risk Analysis.

Entities:  

Keywords:  Colorectal cancer; colorectal lesions; health economic modeling; screening

Mesh:

Year:  2013        PMID: 24172539     DOI: 10.1111/risa.12137

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  11 in total

1.  The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.

Authors:  Marjolein J E Greuter; Johannes Berkhof; Remond J A Fijneman; Erhan Demirel; Jie-Bin Lew; Gerrit A Meijer; Jaap Stoker; Veerle M H Coupé
Journal:  Br J Radiol       Date:  2016-05-19       Impact factor: 3.039

2.  Modeling and Control of Colorectal Cancer.

Authors:  Li-Peng Song; Hao-Yu Wang
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

Review 3.  Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer.

Authors:  Duncan C Thomas
Journal:  Epidemiology       Date:  2017-07       Impact factor: 4.822

4.  Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.

Authors:  Joachim Worthington; Jie-Bin Lew; Eleonora Feletto; Carol A Holden; Daniel L Worthley; Caroline Miller; Karen Canfell
Journal:  PLoS One       Date:  2020-02-03       Impact factor: 3.240

5.  Microsimulation Model for Prevention and Intervention of Coloretal Cancer in China (MIMIC-CRC): Development, Calibration, Validation, and Application.

Authors:  Bin Lu; Le Wang; Ming Lu; Yuhan Zhang; Jie Cai; Chenyu Luo; Hongda Chen; Min Dai
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

6.  Resilience of a FIT screening programme against screening fatigue: a modelling study.

Authors:  Marjolein J E Greuter; Johannes Berkhof; Karen Canfell; Jie-Bin Lew; Evelien Dekker; Veerle M H Coupé
Journal:  BMC Public Health       Date:  2016-09-22       Impact factor: 3.295

7.  The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

Authors:  Elisabeth van der Meijde; Alfons J M van den Eertwegh; Sabine C Linn; Gerrit A Meijer; Remond J A Fijneman; Veerle M H Coupé
Journal:  Cancer Inform       Date:  2016-06-15

8.  Implementation of an optical diagnosis strategy saves costs and does not impair clinical outcomes of a fecal immunochemical test-based colorectal cancer screening program.

Authors:  Jasper L A Vleugels; Marjolein J E Greuter; Yark Hazewinkel; Veerle M H Coupé; Evelien Dekker
Journal:  Endosc Int Open       Date:  2017-11-22

9.  Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening.

Authors:  Maxime E S Bronzwaer; Marjolein J E Greuter; Arne G C Bleijenberg; Joep E G IJspeert; Evelien Dekker; Veerle M H Coupé
Journal:  BMC Cancer       Date:  2018-04-25       Impact factor: 4.430

10.  Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.

Authors:  Francine van Wifferen; Lucie de Jonge; Joachim Worthington; Marjolein J E Greuter; Jie-Bin Lew; Claude Nadeau; Rosita van den Puttelaar; Eleonora Feletto; Jean H E Yong; Iris Lansdorp-Vogelaar; Karen Canfell; Veerle M H Coupé
Journal:  J Med Screen       Date:  2021-12-03       Impact factor: 1.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.